CTRI/2009/091/000999已完成3 期
Efficacy and Tolerability of Ramelteon for treatment of Insomnia - An open-label, randomized, comparative study.
Ranbaxy Laboratories Ltd., Plot No.20, Sector 18, Udyog Vihar Industrial Area, Gurgaon - 122015 , Haryana, India0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of either sex, aged 18 to 60 years, suffering from insomnia characterized by the following criteria at the time of randomization
- •1. Diagnosis of primary insomnia based on DSM-IV* criteria. 2. More than 30 minutes to fall asleep and subjective total sleep time of ≤ 6.5 hours per night (for at least 3 nights per week); and daytime complaints associated with disturbed sleep. 3. Habitual bedtime between 8.30 pm and midnight. 4. Body Mass Index between 16.5 to 30#
- •* DSM-IV Diagnostic criteria for Primary Insomnia
- •1. The predominant complaint is difficulty initiating or maintaining sleep, or nonrestorative sleep, for at least 1 month. 2. The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. 3. The sleep disturbance does not occur exclusively during the course of Narcolepsy, Breathing-Related Sleep Disorder, Circadian Rhythm Sleep Disorder or a Parasomnia.
- •4. The disturbance does not occur exclusively during the course of another mental disorder (e.g., Major Depressive Disorder, Generalized Anxiety Disorder, a Delirium). 5. The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition.
排除标准
- •1. Patients with hypersensitivity to ramelteon or related compounds including melatonin, zolpidem or other non-benzodiazepines with imidazopyridine class. 2. Pregnant or breast-feeding women or women with positive urinary pregnancy test at screening. 3. Patients with clinically significant endocrine, metabolic, hepatic, renal, cardiovascular, gastrointestinal, respiratory, hematological or neurological illness (es). 4. Patients with current psychiatric disorders that are judged by investigator as potentially causing or contributing to insomnia. 5. Patients who suffer from sleep disorder other than primary insomnia including restless leg syndrome and sleep apnea. 6. Patients with SGOT/AST or SGPT/ALT, total serum bilirubin or serum alkaline phosphatase > 1.5 times upper limit of normal or serum creatinine >1.2 times upper limit of normal. 7. Patients receiving treatment with cytochrome P450 enzyme inhibitor drugs like fluvoxamine, itraconazole, ketoconazole, fluconazole or enzyme inducer like rifampin during the last 14 days prior to screening.
- •8. Patients currently receiving treatment with zolpidem or ramelteon or its related compounds. 9. Patients receiving treatment with flurazepam, sertraline and other CNS depressants during last 3 weeks prior to screening. 10. Patients who have received following medications in the period shown in parentheses : Triazolam (1 day); Alprazolam (2 days); Chlordiazepoxide (2 days); Temezepam (2 days); Estazolam (3 days); Lorazepam (3 days); Diazepam (7 days).
- •11. Patients with substance dependence/ abuse in the past one year or with alcohol abuse are ineligible. 12. Patients using tobacco products during night awakenings. 13. Patients with history of seizures or significant head trauma. 14. Patients who travelled across 4 or more time zones or worked on night or rotating shifts in previous 7 days before study initiation or who plan to do the same during the study period. 15. Patients in whom another investigational drug was used within three months prior to entry in this study. 16. Patients who cannot be relied upon to comply with the test procedures or are unwilling to give informed consent.
研究者
相似试验
已完成
不适用
Study of the efficacy and safety of ramelteon in insomnia of diabetes merger under the medical treatment of cancer patientsInsomnia cancer patients under the medical treatment to be complicated by diabetesJPRN-UMIN000014162Division of Diabetes, Endocrinology and Metabolism, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital100
招募中
不适用
Clinical study of the efficacy of ramelteon and zopiclone for nocturiaJPRN-UMIN000004873Kanazawa University40
尚未招募
不适用
The efficacy and safety of ramelteon in prevention of postoperative delirium in the elderlypostoperative deliriumJPRN-UMIN000007584Department of psychiatry, Kobe University Graduate School of Medicine300
招募中
4 期
A clinical trial to study the effectiveness of the drug ramelteon in patients with difficulty in sleeping (insomnia)DepressionAnxietyCTRI/2015/02/005530Sri Aurobindo Medical College Postgraduate Institute120
招募中
不适用
Efficacy of Ramelteon in pharmacoresistant patients with Dravet syndrome aged more than 6 years in the pediatric epileptic centers in seizures controlIRCT20220105053639N1Theracule AS10